Chapter 80
Acne Vulgaris and Acneiform Eruptions
Andrea L. Zaenglein, Emmy M. Graber, & Diane M. Thiboutot

REFERENCES


65. Thiboutot D et al: Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drugs Dermatol 7(Suppl. 6):s3-s10, 2008


68. Webster G et al: Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: A randomized trial. Cutis 67(Suppl. 6):4-9, 2001

69. Leyden JJ et al: Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: A double-blind randomized trial. Cutis 69(Suppl. 2):12-19, 2002


61. Crockett SD et al: A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol 104(10):2387-2393, 2009
73. Suh DH, Kwon TE, Youn JI: Changes of comedonal cytokines and sebum secretion after UV irradiation in acne patients. Eur J Dermatol 12(2):139-144, 2002


149. Perez-Soler R et al: HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum [see comment]. *Oncologist* 10(5):345-356, 2005


